Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-35

AGN on the mechanism of action and pharmacology represents a class of drug called NMDA antagonists except it’s a peptide. It’s part of a group of drugs which have a subclass known a downhill antagonist. It’s a peptide. It is trying to reduce brain injury at point of injury. It’s very short term treatment because it is a glutamate antagonist. Glutamate is used as the power molecule for the brain and it’s what the brain uses to send messages to the whole brain which make communication with the spinal cord passing on the messages onto human organs. Now with glutamate release it causes the release of huge amount of calcium which travels through TRPC receptors which is the cause of neuron death and brain tissue

So the basis for AGN if it stops glutamate it will stop calcium being produced and stop the spread of the initial injury by shutting everything down. But needs to make sure the shut down is not long enough that it effects every organs and the brain as you are shutting down the brain and all its messages. These drug antagonists have been investigating this since 1990 but everytime the drug makes it to phase 3 it fails due to side effects and not showing clinical evidence because the sometimes the exposure of the drug isn’t long enough. So AGN designed a drug to have same properties but long enough to hopefully protect and not cause the unwanted safety issues. That’s the thought process

NYR is a new drug class the first of its kind which is specific calcium influx inhibitor for these TRPC calcium receptors. Receptors 3,6 and 7. Receptors 1,2 and 4 are studied to be receptors that help the brain during injury, while 3,6 and 7 are responsible for the damage. NYR can be given over multiple days and not only treats primary but secondary brain injury which AGN does not however Aptoll does. Secondary brain injury lasts for 3-4 days after initial injury. Aptoll is not a calcium influx inhibitor but stops the production of anti inflammatory mediators in the brain during injury. These calcium receptors that cause damage to the brain tissue are also found in the heart. Receptors 3,6 and 7 are all over the heart so that’s why today announcement the heart was 86 percent protected during a heart attack as well

So NYR protects from primary injury, secondary injury and the heart because it can be continually dosed over multiple days

AGN protects the primary impact and its short term treatment

That’s the summary in a whole. I am invested in both. AGN class of drug has been done multiple times before and always passed into phase 2 and I think AGN will get its pump but its drug class always failed phase 3. NYR based off AGN and Aptoll has a runway through to phase 3 and the first of its kind because its mechanism of action takes into account AGN and Aptoll so will produce overall a stronger result and protects the heart